| TFAP2A Activates S100A2 to Mediate Glutamine Metabolism and Promote Lung Adenocarcinoma Metastasis. | TFAP2A Activates S100A2 to Mediate Glutamine Metabolism and Promote Lung Adenocarcinoma Metastasis.
Zeng T, Ren W, Zeng H, Wang D, Wu X, Xu G., Free PMC Article | 08/27/2024 |
| The interaction between S100A2 and KPNA2 mediates NFYA nuclear import and is a novel therapeutic target for colorectal cancer metastasis. | The interaction between S100A2 and KPNA2 mediates NFYA nuclear import and is a novel therapeutic target for colorectal cancer metastasis.
Han F, Zhang L, Liao S, Zhang Y, Qian L, Hou F, Gong J, Lai M, Zhang H. | 08/11/2024 |
| Multi-omics Analysis Identifies Hypoxia Subtypes and S100A2 as an Immunosuppressive Factor in Cervical Cancer. | Multi-omics Analysis Identifies Hypoxia Subtypes and S100A2 as an Immunosuppressive Factor in Cervical Cancer.
Yang J, Wan S, Zhao M, Cai H, Gao Y, Wang H. | 01/17/2024 |
| NFIC1 inhibits the migration and invasion of MDA-MB-231 cells through S100A2-mediated inactivation of MEK/ERK pathway. | NFIC1 inhibits the migration and invasion of MDA-MB-231 cells through S100A2-mediated inactivation of MEK/ERK pathway.
Zhang J, Wang Z, Liang Z, Jin C, Shi Y, Fan M, Hu X, Wan Y. | 01/14/2023 |
| Transcriptional activation of S100A2 expression by HIF-1alpha via binding to the hypomethylated hypoxia response elements in HCC cells. | Transcriptional activation of S100A2 expression by HIF-1α via binding to the hypomethylated hypoxia response elements in HCC cells.
Yan J, Huang YJ, Huang QY, Liu PX, Wang CS. | 04/30/2022 |
| High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma. | High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.
Zhang Q, Xia T, Qi C, Du J, Ye C., Free PMC Article | 03/5/2022 |
| High S100A2 expression in keratinocytes in patients with drug eruption. | High S100A2 expression in keratinocytes in patients with drug eruption.
Yoshioka M, Sawada Y, Saito-Sasaki N, Yoshioka H, Hama K, Omoto D, Ohmori S, Okada E, Nakamura M., Free PMC Article | 12/11/2021 |
| S100A2: A potential biomarker to differentiate malignant from tuberculous pleural effusion. | S100A2: A potential biomarker to differentiate malignant from tuberculous pleural effusion.
Wang T, Wang N, Zhang L, Liu Y, Thakur A. | 12/4/2021 |
| S100A2 promotes glycolysis and proliferation via GLUT1 regulation in colorectal cancer. | S100A2 promotes glycolysis and proliferation via GLUT1 regulation in colorectal cancer.
Li C, Chen Q, Zhou Y, Niu Y, Wang X, Li X, Zheng H, Wei T, Zhao L, Gao H. | 05/1/2021 |
| S100A2 Silencing Relieves Epithelial-Mesenchymal Transition in Pulmonary Fibrosis by Inhibiting the Wnt/beta-Catenin Signaling Pathway. | S100A2 Silencing Relieves Epithelial-Mesenchymal Transition in Pulmonary Fibrosis by Inhibiting the Wnt/β-Catenin Signaling Pathway.
Huang G, Zhang J, Qing G, Liu D, Wang X, Chen Y, Li Y, Guo S. | 02/6/2021 |
| Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma. | Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma.
Sugiyama T, Ozono S, Miyake H. | 11/21/2020 |
| p53-S100A2 positive feedback loop regulates wound repair process | The p53-S100A2 Positive Feedback Loop Negatively Regulates Epithelialization in Cutaneous Wound Healing.
Pan SC, Li CY, Kuo CY, Kuo YZ, Fang WY, Huang YH, Hsieh TC, Kao HY, Kuo Y, Kang YR, Tsai WC, Tsai ST, Wu LW., Free PMC Article | 10/12/2019 |
| S100A2 and S100P can be used as specific duct markers in eccrine sweat glands, and combined use of S100P or S100A2 with keratins enables easy to distinction between secretory coils and ducts. | Expression of S100A2 and S100P in human eccrine sweat glands and their application in differentiating secretory coil-like from duct-like structures in the 3D reconstituted eccrine sweat spheroids.
Li H, Zhang M, Chen L, Zhang B, Zhang C. | 02/3/2018 |
| These results indicate that oxidative stress impairs the ability of S100 proteins to bind and activate PP5, which in turn modulates the ASK1-mediated signaling cascades involved in apoptosis. | Oxidative Stress Impairs the Stimulatory Effect of S100 Proteins on Protein Phosphatase 5 Activity.
Yamaguchi F, Tsuchiya M, Shimamoto S, Fujimoto T, Tokumitsu H, Tokuda M, Kobayashi R. | 04/1/2017 |
| high S100A2 expression and NSCLC | Expression and clinicopathological significance of S100 calcium binding protein A2 in lung cancer patients of Chinese Han ethnicity.
Wang T, Liang Y, Thakur A, Zhang S, Liu F, Khan H, Shi P, Wang N, Chen M, Ren H. | 02/18/2017 |
| Our results indicate that serum levels of S100A2 and S100A6 are significantly elevated in early stage non-small cell lung cancer | Diagnostic significance of S100A2 and S100A6 levels in sera of patients with non-small cell lung cancer.
Wang T, Liang Y, Thakur A, Zhang S, Yang T, Chen T, Gao L, Chen M, Ren H. | 02/4/2017 |
| S100A2 could have a role in poor prognosis in stage II and III colorectal cancer recurrence | Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer.
Masuda T, Ishikawa T, Mogushi K, Okazaki S, Ishiguro M, Iida S, Mizushima H, Tanaka H, Uetake H, Sugihara K., Free PMC Article | 12/17/2016 |
| The potential of cytoplasmic S100A2 overexpression as a predictor of recurrence risk in oral squamous cell carcinoma patients. | Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients.
Kumar M, Srivastava G, Kaur J, Assi J, Alyass A, Leong I, MacMillan C, Witterick I, Shukla NK, Thakar A, Duggal R, Roychoudhury A, Sharma MC, Walfish PG, Chauhan SS, Ralhan R., Free PMC Article | 03/19/2016 |
| Data show higher expression level of S100A2 in high-invasive cholangiocarcinoma Cell Line suggesting it as potential marker of tumor progression and novel therapeutic target. | Comparative Proteomic Analysis of Human Cholangiocarcinoma Cell Lines: S100A2 as a Potential Candidate Protein Inducer of Invasion.
Wasuworawong K, Roytrakul S, Paemanee A, Jindapornprasert K, Komyod W., Free PMC Article | 03/5/2016 |
| Our investigation complements the current understanding of laryngeal cancer progression. Furthermore, this study supports the concept that enhanced expression of S100A2 may be a promising strategy in developing novel cancer therapeutic drugs. | iTRAQ-based quantitative proteomic analysis on S100 calcium binding protein A2 in metastasis of laryngeal cancer.
Zha C, Jiang XH, Peng SF., Free PMC Article | 01/16/2016 |
| These data demonstrate the importance of S100A2 downstream of the BRCA1/DeltaNp63 signalling axis in modulating transcriptional responses and enforcing growth control mechanisms through destabilisation of mutant p53. | S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.
Buckley NE, D'Costa Z, Kaminska M, Mullan PB., Free PMC Article | 10/25/2014 |
| loss of S100A2 expression contributes to Ggastric cancer development and progression. | Clinical significance of S100A2 expression in gastric cancer.
Liu YF, Liu QQ, Wang X, Luo CH. | 06/14/2014 |
| S100A2 protumorigenic actions and its involvement in TGF-beta-mediated cancer cell invasion and epithelial-mesenchymal transition. | Protumorigenic actions of S100A2 involve regulation of PI3/Akt signaling and functional interaction with Smad3.
Naz S, Bashir M, Ranganathan P, Bodapati P, Santosh V, Kondaiah P. | 04/5/2014 |
| Expression of S100A2 in cholangiocarcinoma cells significantly correlated with the histological grade, lymph node metastasis, clinical stage, and a poor survival rate of the patients. Thus it is a strong tumor marker for the cancer. | Clinicopathological significance of S100 protein expression in cholangiocarcinoma.
Sato Y, Harada K, Sasaki M, Nakanuma Y. | 03/29/2014 |
| Data indicate that S100A2 expression predicts longer disease-free survival (DFS) and overall survival (OS) in patients treated with adjuvant therapy and should be evaluated as a predictive biomarker. | S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.
Bachet JB, Maréchal R, Demetter P, Bonnetain F, Cros J, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Vaillant JC, André T, Closset J, Salmon I, Emile JF, Van Laethem JL. | 09/21/2013 |